

# Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2020

<https://marketpublishers.com/r/AD5FC624105EN.html>

Date: June 2020

Pages: 3103

Price: US\$ 2,500.00 (Single User License)

ID: AD5FC624105EN

## Abstracts

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Myelocytic Leukemia - Pipeline Review, H1 2020, provides an overview of the Acute Myelocytic Leukemia (Oncology) pipeline landscape.

Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the blood stream and spread to the other parts of the body. Symptoms for AML include fatigue, fever, bleeding, breathing problems, weight loss. The predisposing factors involved are exposure to radiation or chemicals and smoking. Treatment includes chemotherapy, transfusions, transplant and surgery.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Myelocytic Leukemia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Acute Myelocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Myelocytic Leukemia (Oncology) pipeline guide also reviews of key players

involved in therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 3, 17, 137, 137, 2, 7, 236, 44 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 18, 20, 5, 1, 48 and 27 molecules, respectively. Acute Myelocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (Oncology).

The pipeline guide reviews pipeline therapeutics for Acute Myelocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Acute Myelocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Acute Myelocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Acute Myelocytic Leukemia (Oncology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Acute Myelocytic Leukemia (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Overview

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics

Development

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics

Assessment

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Companies Involved  
in Therapeutics Development

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Drug Profiles

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued  
Products

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Product

Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by 4SC AG, H1 2020

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2020

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AB Science SA, H1 2020

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AbbVie Inc, H1 2020

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ABL Bio Inc, H1 2020

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Accent Therapeutics Inc, H1 2020

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Acepodia Biotech Inc, H1 2020

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Acrotech Biopharma LLC, H1 2020

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Actinium Pharmaceuticals Inc, H1 2020

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Adlai Nortye Biopharma Co Ltd, H1 2020

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Advanced BioDesign, H1 2020

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Advenchen Laboratories LLC, H1 2020

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aeglea

BioTherapeutics Inc, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

4SC AG

A. Menarini Industrie Farmaceutiche Riunite Srl

AB Science SA

AbbVie Inc

ABL Bio Inc

Accent Therapeutics Inc

Acepodia Biotech Inc

Acrotech Biopharma LLC

Actinium Pharmaceuticals Inc

Adlai Nortye Biopharma Co Ltd

Advanced BioDesign

Advenchen Laboratories LLC

Aeglea BioTherapeutics Inc

Affichem SA

Agenus Inc

Agios Pharmaceuticals Inc

AI Therapeutics

Aileron Therapeutics Inc

AIMM Therapeutics BV

Aleta Biotherapeutics Inc



Alfasigma SpA  
Allogene Therapeutics Inc  
Amgen Inc  
Amphivena Therapeutics Inc  
Amplia Therapeutics Ltd  
Angiocrine Bioscience Inc  
Anhui Anke Biotechnology (Group) Co Ltd  
ANP Technologies Inc  
Antengene Corp  
Antisense Therapeutics Ltd  
AnyGen Co Ltd  
APIM Therapeutics AS  
Aprea Therapeutics AB  
AptaBio Therapeutics Inc  
Aptevo Therapeutics Inc  
Aptose Biosciences Inc  
Aravive Inc  
Arcellx Inc  
Argenx SE  
Arog Pharmaceuticals Inc  
Arrien Pharmaceuticals LLC  
Arvinas Inc  
Ascentage Pharma Group International  
Aslan Pharmaceuticals Ltd  
Astellas Pharma Inc  
Astex Pharmaceuticals Inc  
AstraZeneca Plc  
Atara Biotherapeutics Inc  
Athenex Inc  
ATP Biopharm  
AUM Biosciences Pte Ltd  
Auransa Inc  
Aurigene Discovery Technologies Ltd  
Avidin Ltd  
AVROBIO Inc  
Avvinity Therapeutics Ltd  
Bantam Pharmaceutical LLC  
Bayer AG  
BCI Pharma SA

Beam Therapeutics Inc  
Beijing Immunochina Medical Science & Technology Co Ltd  
Bellicum Pharmaceuticals Inc  
BerGenBio ASA  
Betta Pharmaceuticals Co Ltd  
Bio-Cancer Treatment International Ltd  
Bio-Path Holdings Inc  
Biokine Therapeutics Ltd  
BioLineRx Ltd  
BioMed Valley Discoveries Inc  
Bionomics Ltd  
BioSight Ltd  
BioTheryX Inc  
BioXcel Therapeutics Inc  
BiVictriX Therapeutics Ltd  
bluebird bio Inc  
Blueprint Medicines Corp  
Boehringer Ingelheim International GmbH  
Boryung ViGenCell Inc  
Boston Biomedical Inc  
BoYen Therapeutics Inc  
Bridge Medicines LLC  
Bristol-Myers Squibb Co  
Canqura Oncology AB  
Cardiff Oncology Inc  
Carrick Therapeutics UK Ltd  
Catalent Inc  
CellCentric Ltd  
Cellestis SA  
Cellerant Therapeutics Inc  
Cellipse SAS  
Cellular Biomedicine Group Inc  
Celularity Inc  
Celyad Oncology  
Centrose LLC  
Changzhou Qianhong Bio-Pharma Co Ltd  
CharlestonPharma LLC  
Checkpoint Therapeutics Inc  
Chimerix Inc

Chongqing Precision Biotech Co Ltd  
Chordia Therapeutics Inc  
Chugai Pharmaceutical Co Ltd  
Clear Creek Bio Inc  
Cleave Therapeutics Inc  
Colmmune Inc  
Constellation Pharmaceuticals Inc  
CRISPR Therapeutics AG  
CrystalGenomics Inc  
CSPC Pharmaceutical Group Ltd  
Cue Biopharma Inc  
Cullinan Oncology LLC  
CuronBiotech Inc  
Cyclacel Pharmaceuticals Inc  
Cytovia Inc  
Daiichi Sankyo Co Ltd  
Dalriada Therapeutics Inc  
DC Prime BV  
Deciphera Pharmaceuticals Inc  
Delta-Fly Pharma Inc  
Demuris Ltd  
Denovo Biopharma LLC  
DiNonA Inc  
Dong-A ST Co Ltd  
Eli Lilly and Co  
Emercell SAS  
Eminent Biosciences  
EntreChem SL  
Enzyme by Design Inc  
Epigene Therapeutics Inc  
Epizyme Inc  
Escend Pharmaceuticals Inc  
ExCellThera Inc  
Exonate Ltd  
Expression Therapeutics LLC  
F. Hoffmann-La Roche Ltd  
Fate Therapeutics Inc  
Fimecs Inc  
Flavocure Biotech LLC

Forma Therapeutics Inc  
Fujifilm Holdings Corp  
Gadeta BV  
Gamida Cell Ltd  
GC Pharma  
GEMoaB Monoclonals GmbH  
Genentech Inc  
Genmab AS  
Genosco Inc  
Genus Oncology LLC  
Geron Corp  
Gilead Sciences Inc  
GlaxoSmithKline Plc  
GlycoMimetics Inc  
Glycostem Therapeutics BV  
GO Therapeutics Inc  
Golden Biotechnology Corp  
GT Biopharma Inc  
H3 Biomedicine Inc  
Hanmi Pharmaceuticals Co Ltd  
Hebei Senlang Biotechnology Inc Ltd  
HEC Pharm Co Ltd  
Hefei Cosource Pharmaceutical Inc  
Helocyte Biosciences Inc  
HemoGenyx LLC  
HemoGenyx Pharmaceuticals Plc  
HiFiBiO SAS  
HighPass Bio Inc  
Hillstream BioPharma Inc  
Hinova Pharmaceuticals Inc  
Hoverink Biotechnologies Inc  
HRAIN Biotechnology Co Ltd  
Hummingbird Bioscience Pte Ltd  
Hunan Siweikang Therapeutics Ltd  
Hutchison MediPharma Ltd  
Hybrigenics SA  
I-Mab Biopharma Co Ltd  
iCell Gene Therapeutics LLC  
IGF Oncology LLC

IGM Biosciences Inc  
Imago BioSciences Inc  
ImCheck Therapeutics SAS  
Immune Onc Therapeutics Inc  
Immune System Key Ltd  
ImmunoGen Inc  
Immunomedics Inc  
Inatherys  
Incuron LLC  
Incysus Therapeutics Inc  
Incyte Corp  
Inflection Biosciences Ltd  
Inmune Bio Inc  
Innovation Pharmaceuticals Inc  
Intellia Therapeutics Inc  
Interprotein Corp  
Intra-Immug Pvt Ltd  
Io Therapeutics Inc  
Iterion Therapeutics  
Jasper Therapeutics Inc  
Jazz Pharmaceuticals Plc  
Jeil Pharmaceutical Co Ltd  
Jiangsu Aidea Pharmaceutical Co Ltd  
Jiangsu Hengrui Medicine Co Ltd  
Johnson & Johnson  
JSK Therapeutics Inc  
Jubilant Therapeutics Inc  
Juno Therapeutics Inc  
Juventas Cell Therapy Ltd  
JW Pharmaceutical Corp  
Kainos Medicine Inc  
Kartos Therapeutics Inc  
Karyopharm Therapeutics Inc  
Keystone Nano Inc  
Kiadis Pharma NV  
KinaRx LLC  
KisoJi Biotechnology Inc  
Komipharm International Co Ltd  
Konruns Pharmaceutical Co Ltd

Kura Oncology Inc  
Kurome Therapeutics Inc  
Kymera Therapeutics LLC  
Laekna Therapeutics Shanghai Co Ltd  
Lai Corporation Pty Ltd  
Lead Discovery Center GmbH  
Les Laboratoires Servier SAS  
Leukos Biotech SL  
Lineage Cell Therapeutics Inc  
Lumos Pharma Inc  
Mablink Bioscience  
Machavert Pharmaceuticals LLC  
MacroGenics Inc  
Magenta Therapeutics Inc  
Mana Therapeutics Inc  
Marker Therapeutics Inc  
Mateon Therapeutics Inc  
Maxinovel Pharmaceuticals  
MedAbome Inc  
MediGene AG  
Medivir AB  
MEI Pharma Inc  
Merck & Co Inc  
Merck KGaA  
Merus NV  
Meryx Inc  
Millennium Pharmaceuticals Inc  
Minneamrita Therapeutics LLC  
Miragen Therapeutics Inc  
MiRx Pharmaceuticals LLC  
Molecular Templates Inc  
Molecules For Health Inc  
Moleculin Biotech LLC  
MolMed SpA  
Multitude therapeutics Inc  
Mustang Bio Inc  
MyeloRx LLC  
Nanjing Iaso Biotherapeutics Co Ltd  
Nanjing Legend Biotech Co Ltd

Nanjing Sanhome Pharmaceutical Co Ltd  
Nanovalent Pharmaceuticals Inc  
NantKwest Inc  
Nemucore Medical Innovations Inc  
Newave Pharmaceutical Inc  
NexImmune Inc  
Nkarta Inc  
NMS Group SpA  
Nohla Therapeutics Inc  
Northlake International LLC  
Novartis AG  
OHM Oncology  
Omeros Corp  
Oncoceutics Inc  
Oncoheroes Biosciences Inc  
Oncolmmune Inc  
Oncopeptides AB  
OncoTartis Inc  
OncoTherapy Science Inc  
Oncternal Therapeutics  
Ono Pharmaceutical Co Ltd  
Opsyon  
Orano Med LLC  
Orca Biosystems Inc  
Orsenix Holdings BV  
Oryzon Genomics SA  
Otsuka Holdings Co Ltd  
Oxford BioTherapeutics Ltd  
Oxstem Ltd  
Pacylex Pharmaceuticals Inc  
PentixaPharm GmbH  
Peptron Inc  
PersonGen Biomedicine Suzhou Co Ltd  
Petra Pharma Corp  
Pfizer Inc  
Pharma Mar SA  
Pharos I&BT Co Ltd  
Phebra Pty Ltd  
Phi Pharma SA

Philogen SpA  
PhoreMost Ltd  
Picobella LLC  
Pimera Inc  
PiNK Biopharma Ltd  
Pinotbio Inc  
Pinteon Therapeutics Inc  
Plexxikon Inc  
PRISM Pharma Co Ltd  
Promutech Pharmaceuticals Inc  
Protheragen Inc  
Provectus Biopharmaceuticals Inc  
Provention Bio Inc  
PTC Therapeutics Inc  
PYCTX Ltd  
Qualigen Therapeutics Inc  
Qurient Co Ltd  
Race Oncology Ltd  
Rafael Pharmaceuticals Inc  
Rasna Therapeutics Inc  
Regenacy Pharmaceuticals LLC  
Rhizen Pharmaceuticals SA  
Rich Pharmaceuticals Inc  
Rubius Therapeutics Inc  
Ryvu Therapeutics SA  
Salarius Pharmaceuticals Inc  
Samumed LLC  
Sandhill Therapeutics Inc  
Sanofi  
Sapience Therapeutics Inc  
Sareum Holdings Plc  
Seattle Genetics Inc  
SELLAS Life Sciences Group Inc  
Senhwa Biosciences Inc  
SFA Therapeutics LLC  
Shanghai Fosun Pharmaceutical (Group) Co Ltd  
Shanghai icell Biotechnology Co Ltd  
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd  
Shijiazhuang Yiling Pharmaceutical Co Ltd



SignalChem Lifesciences Corp  
Sino Biopharmaceutical Ltd  
SiNOPSEE Therapeutics Pte Ltd  
SL Bigen Inc  
SMET Pharmaceutical Inc  
Solasia Pharma KK  
SpecificiT Pharma Inc  
Spectrum Pharmaceuticals Inc  
Alkido Pharma Inc  
SphingoGene Inc  
Stelexis Therapeutics LLC  
Storm Therapeutics Ltd  
Sumitomo Dainippon Pharma Co Ltd  
Sunesis Pharmaceuticals Inc  
Surface Oncology Inc  
SuviCa Inc  
Suzhou Zelgen Biopharmaceutical Co Ltd  
Synactix Pharmaceuticals Inc  
Syndax Pharmaceuticals Inc  
SYNIMMUNE GmbH  
Tacitus Therapeutics Inc  
TaiGen Biotechnology Co Ltd  
Takara Bio Inc  
Takeda Pharmaceutical Co Ltd  
TC BioPharm Ltd  
TeamedOn International LLC  
Teva Pharmaceutical Industries Ltd  
TheraPharm Deutschland GmbH  
Tiziana Life Sciences Plc  
Tmunity Therapeutics Inc  
Toko Pharmaceutical Industries Co Ltd  
Tolero Pharmaceuticals Inc  
TOLREMO Therapeutics AG  
TOT Biopharm Co Ltd  
Treadwell Therapeutics Inc  
Trillium Therapeutics Inc  
Triphase Accelerator Corp  
UbiVac LLC  
Vertex Pharmaceuticals Inc

Veru Inc  
Vessel Scientific LLC  
Vichem Chemie Research Ltd  
VioQuest Pharmaceuticals Inc (Inactive)  
Viralytics Pty Ltd  
VM Discovery Inc  
Vor BioPharma Inc  
Vyriad Inc  
Wugen Inc  
Wuhan Bio-Raid Biotechnology Co Ltd  
XEME BioPharma Inc  
Xencor Inc  
Y-Biologics Inc  
Y-mAbs Therapeutics Inc  
Yungjin Pharm Co Ltd  
Zenith Epigenetics Ltd  
Zentalis Pharmaceuticals LLC  
ZIOPHARM Oncology Inc  
Zovis Pharmaceuticals

## I would like to order

Product name: Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/AD5FC624105EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AD5FC624105EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

